HopeStage
Back to all studies
CompletedNCT00142909

Lofexidine with naltrexone to reduce stress-related opioid relapse

About this titleRead the official source — NCT00142909
Medication studyAges 18+United StatesAddiction
The study in practice

Understand this study

Who was this study for?

Listed age limits: from 18 years.

Listed locations
New HavenSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateFebruary 2005
Recruitment status
Completed
Enrollment listed in the registry
86
Sponsor
Yale University
Sponsor type
University
Study type
Drug
Intervention type
Drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States
Age range
Over 18 Years
Official registry ID
NCT00142909
Official title
Show the full official title

Lofexidine: Enhancing Naltrexone Treatment for Opiate Addiction

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

New Haven

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Yale University, a university.

Did this study involve medication?

Yes. The study involved medication, including Lofexidine and Placebo.

Who was this study for?

Listed age limits: from 18 years.

Want to explore more studies?

Explore studies